# STARLIGHT-1 (NCT06343311)

> T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06343311
- Phase: PHASE1, PHASE2
- Status: RECRUITING
- Sponsor: Estrella Immunopharma, Inc.
- Conditions: B-Cell Non-Hodgkin's Lymphoma (NHL); Lymphoma, Non-Hodgkins; Lymphomas Non-Hodgkin's B-Cell; Non-Hodgkin Lymphoma; Non-Hodgkin's Lymphoma; Large B-Cell Lymphoma; Lymphoma, Non-Hodgkin's, Adult; Lymphoma; Refractory Non-Hodgkin Lymphoma; Relapsed Non-Hodgkin Lymphoma; Lymphoma, Non-Hodgkin; HIV Associated Lymphoma; CNS Lymphoma; High-grade B-cell Lymphoma; Refractory B-Cell Non-Hodgkin Lymphoma
- Interventions: EB103
- Enrollment: 27
- Primary outcome: To assess the safety and tolerability of EB103.
- Primary outcome: To determine the Recommended Phase II Dose (RP2D) of EB103 (in Phase 1, Dose Escalation)

## Commentary we found

- YouTube: 3
- Podcasts: 2

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=starlight-1-nct06343311